The most recent trading session ended with Enveric Biosciences, Inc. (ENVB) standing at $0.90, reflecting a -0.56% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow saw an upswing of 0.4%, while the tech-heavy Nasdaq appreciated by 2.03%.

Coming into today, shares of the company had lost 10% in the past month. In that same time, the Medical sector lost 5.2%, while the S&P 500 lost 3.15%.

The investment community will be closely monitoring the performance of Enveric Biosciences, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of -$0.61, indicating a 72.52% growth compared to the equivalent quarter last year.

Investors should also note any recent changes to analyst estimates for Enveric Biosciences, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 25.61% higher within the past month. Enveric Biosciences, Inc. presently features a Zacks Rank of #1 (Strong Buy).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 30% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Enveric Biosciences, Inc. (ENVB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research